<DOC>
	<DOCNO>NCT00579306</DOCNO>
	<brief_summary>The goal trial determine prognostic significance elevate level inflammatory blood marker people experience small subcortical stroke enrol Secondary Prevention Small Subcortical Strokes ( SPS3 ) trial .</brief_summary>
	<brief_title>Levels Inflammatory Markers Treatment Stroke—An SPS3 Ancillary Study</brief_title>
	<detailed_description>Inflammation increasingly recognize play central role atherosclerosis coronary artery disease . And , peripheral blood marker inflammation associate incident recurrent cardiac event . The relationship risk markers—which potential modified—to prognosis ischemic stroke less clear . The Levels Inflammatory Markers Treatment Stroke ( LIMITS ) study address question role inflammatory marker secondary stroke prevention cost-effective manner use well-established framework Secondary Prevention Small Subcortical Strokes ( SPS3 ) trial . The SPS3 trial ongoing Phase 3 , multicenter secondary stroke prevention trial focus prevent stroke recurrence people small vessel ischemic stroke , lacunes . The overall purpose LIMITS study determine serum level inflammatory markers—such hsCRP , serum amyloid A ( SAA ) , CD40 ligand ( CD40L ) , monocyte chemoattractant protein-1 ( MCP-1 ) —predict recurrent stroke vascular event among people history small artery ischemic stroke . The project also determine marker predict people respond best dual antiplatelet therapy clopidogrel aspirin . The specific aim LIMITS determine hsCRP , SAA , CD40L , MCP-1 level independent risk factor recurrent ischemic stroke , recurrent ischemic stroke , myocardial infarction , death participant SPS3 trial adjust demographic traditional stroke risk factor , treatment , use prospective cohort people small subcortical stroke SPS3 trial . LIMITS also aim compare efficacy dual versus single antiplatelet therapy among participant group without elevated baseline inflammatory marker level outcome . ) recurrent stroke , b . ) recurrent ischemic stroke , myocardial infarction , death .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<criteria>Patient must randomize within 6 month qualify small subcortical stroke ( S3 ) subcortical TIA One follow lacunar syndrome : PMH ; pure sensory stroke ; sensorimotor stroke ; ataxic hemiparesis ; dysarthria ; hemiballism ; PMH facial sparing , horizontal gaze palsy , contralateral III palsy , contralateral VI palsy ; Ataxia contralateral III palsy ; pure dysarthria Absence cortical dysfunction ( aphasia , apraxia , agnosia ) No ipsilateral cervical carotid stenosis ( &gt; = 50 % ) S3 hemispheric No majorrisk cardioembolic source require anticoagulation MRI evidence S3 &gt; =2.0 cm diameter DWI/bright lesion FLAIR/T2 &lt; =1.5cm hypointense lesion FLAIR/T1 , correspond qualify event ( required brainstem event ) OR multiple S3 cerebral hemisphere &lt; =1.5cm hypointense lesion FLAIR/T1 AND absence cortical stroke large subcortical stroke . Disabling stroke ( Ranking Scale &gt; = 4 ) Prior hemorrhagic stroke Age &lt; 30 year High risk bleeding ( recurrent GI GU bleeding , active peptic ulcer disease , etc ) Need longterm use anticoagulant antiplatelet agent . Prior cortical retinal stroke / TIA Prior ipsilateral carotid endarterectomy hemispheric S3 Impaired renal function : GFR &lt; 40 cc/min Intolerance/contraindication aspirin clopidogrel Adjusted Folstein MMSE &lt; 24 Medical contraindication MRI Pregnancy childbearing potential without contraception Other specific cause stroke ( e.g . dissection , vasculitis , drug abuse )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>stroke</keyword>
	<keyword>cerebrovascular accident</keyword>
</DOC>